32 results about "Respirovirus" patented technology

The invention provides methods of preventing and / or treating infection by a respiratory virus such as respiratory syncytial virus (RSV), particularly reducing infection and / or one or more symptoms of respiratory virus infection. A polynucleotide comprising an immunostimulatory sequence (an “ISS”) is administered to an individual which is at risk of being exposed to a respiratory virus, has been exposed to a respiratory virus or is infected with a respiratory virus. The ISS is administered without any antigens of the respiratory virus. Administration of the ISS results in reduced incidence and / or severity of one or more symptoms of respiratory virus infection.

The invention relates to a medicine compound with interferon. Wherein, said compound can be used to prepare the medicine that prevents and resists virus infection of respiratory tract. Said compound contains interferon and other auxiliary materials. Wherein, said interferon can be alpha2b, alpha1b, beta, Omega, k, lambada, epsilon and other I type; said auxiliary materials contains protector andbaffle solution; and said interferon can be recombined interferon or / and the ones made by other methods; the auxiliary materials can be acidic buffer, protein, manna sugar, polyose, and benzoic alcohol to realize baffle, stabilize and corrosion-resistant functions.

The invention provides siRNA compositions that interfere with viral replication in respiratory viral infections, including respiratory syncytial virus and avian influenza A, including the H5N1 strain. The invention further provides uses of the siRNA compositions to inhibit expression of viral genes in respiratory virus-infected cells, and to uses in the treatment of respiratory virus infections in a subject. Generally the invention provides polynucleotide that includes a first nucleotide sequence of 15 to 30 bases that targets the genome of a respiratory syncytial virus or an influenza A virus, a complement thereof, a double stranded polynucleotide or a hairpin polynucleotide. Additionally the invention provides vectors, cells and pharmaceutical compositions containing siRNA sequences.

The invention discloses a biological marker for diagnosing respiratory syncytial virus infection of children. The biological marker can be used for assisting to diagnose the respiratory syncytial virus infection of the children. The invention also discloses a combination of at least two biological markers correlated with the respiratory syncytial virus infection of the children; the respiratory syncytial virus infection of the children can be combined with a bioinformatics method to use; the invention further discloses a product correlated with the biological marker.

The invention discloses an NGS primer set and a kit for respiratory RNA pathogens (flu A, flu B, syncytial virus, and new crown). The primer set consists of 594 primer sequences. The present invention specifically designs 594 primers for influenza A, influenza B, syncytial virus and novel coronavirus genomes, covering the entire viral genome, improving the detection of viruses and greatly improving the possibility of full-length detection of viral genome sequences without PCR amplification. It can quickly achieve full coverage of the viral genome.

The invention discloses a biological marker for diagnosing respiratory syncytial virus infection of children. The biological marker can be used for assisting to diagnose the respiratory syncytial virus infection of the children. The invention also discloses a combination of at least two biological markers correlated with the respiratory syncytial virus infection of the children; the respiratory syncytial virus infection of the children can be combined with a bioinformatics method to use; the invention further discloses a product correlated with the biological marker.

This invention relates to the field of medicine and concerns a method for the prophylaxis or treatment of diseases caused by RNA- and DNA-containing viruses, and concomitant diseases, which envisages the use of an effective amount of a compound of general formula I or a pharmaceutically acceptable salt thereof. The invention also relates to methods for producing the aforesaid compounds, and to pharmaceutical compositions for the prophylaxis or treatment of diseases caused by RNA- and DNA-containing viruses, which contain an effective amount of a compound of general formula I or a pharmaceutically acceptable salt thereof. The invention solves the problem of providing a novel agent effective in the treatment of diseases caused by RNA-containing viruses belonging to the enterovirus genus, the metapneumovirus genus, the pneumovirus genus, the respirovirus genus or the alphacoronavirus genus, and DNA-containing viruses belonging to the adenovirus family and the herpesvirus family, and also effective in the prophylaxis and treatment of asthma exacerbations, chronic obstructive pulmonary disease, cystic fibrosis, conjunctivitis, gastroenteritis, hepatitis and myocarditis, and in the prophylaxis and treatment of rhinorrhea, acute and infectious rhinitis, pharyngitis, nasopharyngitis, tonsillitis, laryngitis, laryngotracheitis, laryngotracheobronchitis, bronchitis, bronchiolitis, pneumonia or obstructive airways syndrome.

The invention discloses a high-flux non-diagnostic detection method for 13 respiratory viruses based on a novel suspension chip technology. Aiming at the specificity gene sequences of 13 pieces or types of respiratory viruses, such as influenza viruses A and B, auxiliary influenza viruses 1 and 3, coronavirus SARS-CoV and CoV-NL63, respiratory syncytial viruses A and B, adenoviruses B and E, a rhinovirus, a human metapneumovirus and an enterovirus, 13 pairs of primers and corresponding specificity probes are designed; by multiple polymerase chain reaction (PCR) amplification and TSPE reaction, X-TAG nucleic acid fragment and biotin are respectively marked with corresponding gene fragments; the marked fragments are combined with corresponding encoded micro balls; and a suspension chip scanner is used for performing detection. The high-flux non-diagnostic detection method can accurately detect 13 respiratory viruses and subtypes of the 13 respiratory viruses; the probes do not generate cross reaction; the specificity is high; and the sensitivity is high. A high-flux, quick and accurate technical platform is capable of simultaneously detecting various respiratory viruses; technical equipment is supplied to the detection of pathogens of sudden respiratory tract infectious diseases; and information can be timely supplied to the handling of infectious disease epidemic situation burst.

The invention provides novel high-sensitivity respiratory virus nucleic acid NASBA (nucleic acid sequence based amplification) primers. A respiratory virus conservative area is selected, and a promoter sequence capable of being recognized by T7 RNA (ribose nucleic acid) polymerase is formed at the 5' terminal of one of the synthesized primers. The invention further provides a novel high-sensitivity respiratory virus nucleic acid NASBA detection method. T7 RNA polymerase promoter sequences are added to the 5' terminals of the two primers complementary to two ends of a respiratory virus RNA sequence, so that when the primers enter a circulation phase, RNA sequences [RNA(+)] consistent with a template sequence can be synthesized, RNA sequences [RNA(-)] complementary to a template RNA sequence can be synthesized, and the detection sensitivity of viral nucleic acid is greatly improved; a throat swab sample of a patient can be directly used for amplification, a reverse transcription process is not required, and the operation time is saved.

The present invention is related to detecting respiratory diseases using molecular markers as prognostic tool of the evolution of respiratory infection cases. Concretely, during the differential diagnostic of respiratory infections caused by the Syncytial Respiratory Virus and human Metapneumovirus, it will be established the expression pattern of the severity markers of IL-3, IL-33 and IL12p40. The expression pattern of the molecular markers can be defined in biological samplers using ELISA assays, flow cytometry or PCR in real time. The confirmation of the etiological agent of the infection in combination to the pattern definition of the molecular markers IL-3, IL-33 and IL12p40 will indicate a prognostic of the disease severity.